Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L. lactis CKDB001 in Early Alzheimer's Disease
NCT07496021Recruiting
- Sponsor
- CKD BiO
- Start
- Feb 2026
- Primary completion
- May 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, double-blind trial in Alzheimer's disease (AD) comparing L. lactis CKDB001 with Placebo (2 arms). Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale 14 total score at 24 weeks, Alzheimer's Disease Assessment Scale-Cognitive Subscale 14 memory box score at 24 weeks and 7 more. Started Feb 2026; status: recruiting.
02
Drugs
Lactobacillus delbrueckii subsp. lactis CKDB001
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07496021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07496021.